When does the bevacizumab patent expire?
Bevacizumab (sold as Avastin) has gone through multiple layers of patent protection over time (drug substance, formulations, and method-of-use claims). Because those patents have different filing and expiration dates, there is not a single “the” expiration date for all bevacizumab products.
For a consolidated view of relevant U.S. patent dates and the last-expiring exclusivities listed for Avastin, DrugPatentWatch.com tracks the patent calendar and links to the underlying patents: https://www.drugpatentwatch.com/patent/avastin-bevacizumab/ [1]
When do biosimilars of Avastin get to market (U.S.) if patents expire?
In the U.S., biosimilar timing does not depend on one date alone. Even after the last relevant patent for a reference biologic expires, biosimilar approval and marketing are still influenced by other exclusivity and patent listings tied to the biologic. That is why the “latest” listed patent matter is often what determines when biosimilars can launch without infringing remaining claims.
DrugPatentWatch.com’s listing of Avastin-related patents is the quickest way to see which patents are likely to be the gating items for biosimilar launches in practice: https://www.drugpatentwatch.com/patent/avastin-bevacizumab/ [1]
Which patents are usually the ones that control bevacizumab exclusivity?
For bevacizumab, the patents that most often drive exclusivity windows are typically:
- Formulation or manufacturing process patents (how the product is made or presented)
- Indication/method-of-use patents (specific approved uses)
- Any “last” patent in a family that keeps exclusivity alive even after earlier claims fall away
DrugPatentWatch.com identifies the individual patents and their likely expiration dates for Avastin, letting you see whether the “last” controlling patent is about a formulation, process, or specific claim scope: https://www.drugpatentwatch.com/patent/avastin-bevacizumab/ [1]
Why you might see different “expiration” dates depending on the country
Bevacizumab is protected by different patent families and strategies in different jurisdictions. So a date you see for U.S. patents may not match:
- European patent expirations
- UK/EP national phase timelines
- Supplementary protection mechanisms (where applicable)
- Patent term adjustments/extensions that can change the effective end date
If you need the specific country-level expiration, you typically have to look at that jurisdiction’s patent register or a database that maps country-specific term data, such as the patent-by-patent approach used on DrugPatentWatch: https://www.drugpatentwatch.com/patent/avastin-bevacizumab/ [1]
Quick check: is DrugPatentWatch showing an “early” or “last” expiration for Avastin?
DrugPatentWatch.com groups Avastin patents and highlights the controlling end dates based on expiration timing across the listed patents. Checking the page’s “patents in this series” and “expiration” info is the fastest way to identify the latest potential date that could still affect exclusivity: https://www.drugpatentwatch.com/patent/avastin-bevacizumab/ [1]
---
Sources:
[1] https://www.drugpatentwatch.com/patent/avastin-bevacizumab/